Welcome to the Information Website for the In re Pfizer Inc. Securities Litigation
Update: The trial for this matter is currently scheduled to begin on September 9, 2014.
If you purchased and/or otherwise acquired Pfizer, Inc. (“Pfizer” or “PFE”) common stock between and including October 31, 2000 and October 19, 2005, you may have important legal rights.
The main complaint in this Action is that Pfizer and the Individual Defendants, who were allegedly controlling officers and/or directors of Pfizer, made materially false and misleading statements and omitted material information from Pfizer’s public reports and documents about the cardiovascular risks associated with Celebrex and Bextra. As a result of these misrepresentations, Plaintiffs allege that the price of Pfizer common stock during the Class Period was artificially inflated. Plaintiffs allege that once the truth about these cardiovascular risks began to emerge, the price of Pfizer common stock declined in value and Class Members suffered losses. Plaintiffs also allege that three former officers and/or directors of Pfizer sold shares of Pfizer stock during the Class Period while in possession of material information about the cardiovascular safety of Celebrex and Bextra that was not disclosed to the public. Plaintiffs are asserting claims under several provisions of the Federal Securities Exchange Act of 1934 (the “Exchange Act”).
Defendants continue to deny Plaintiffs' factual allegations and the legal claims against them. Defendants have moved for summary judgment, asking the Court to dismiss the claims against them and end the case. Plaintiffs intend to oppose that motion. The parties also are preparing other pre-trial motions designed to narrow the issues to be tried before a jury in the event that Defendants' summary judgment motion is not granted.
The Frequently Asked Questions page of this website has more information on your rights as a class member in this Action.
Epiq Systems © 2012 | All Rights Reserved